Freeline Therapeutics Holdings PLC ADR (FRLN): Price and Financial Metrics


Freeline Therapeutics Holdings PLC ADR (FRLN): $0.76

0.07 (+10.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FRLN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

FRLN Stock Price Chart Interactive Chart >

Price chart for FRLN

FRLN Price/Volume Stats

Current price $0.76 52-week high $15.40
Prev. close $0.69 52-week low $0.65
Day low $0.70 Volume 18,700
Day high $0.76 Avg. volume 686,128
50-day MA $0.93 Dividend yield N/A
200-day MA $2.06 Market Cap 27.24M

Freeline Therapeutics Holdings PLC ADR (FRLN) Company Bio


Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. It develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Nathwani on April 3, 2020 and is headquartered in Stevenage, the United Kingdom.


FRLN Latest News Stream


Event/Time News Detail
Loading, please wait...

FRLN Latest Social Stream


Loading social stream, please wait...

View Full FRLN Social Stream

Latest FRLN News From Around the Web

Below are the latest news stories about Freeline Therapeutics Holdings plc that investors may wish to consider to help them evaluate FRLN as an investment opportunity.

2 Net Current Asset Value Stocks to Consider

Short-term investors could be interested in these businesses

Yahoo | February 21, 2022

Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™

FLT190 well-tolerated with promising early efficacy in Fabry disease including sustained α-Gal A expression up to two years GALILEO-1, a first-in-human, open-label, international, multicenter Phase 1/2 clinical trial evaluating FLT201 in Gaucher disease Type 1 initiated LONDON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people wi

Yahoo | February 8, 2022

Freeline grants inducement options to three new employees

Freeline Therapeutics (NASDAQ:FRLN) granted three newly hired employees non-statutory options to purchase 66.4K of its shares. Each of the options has an exercise price of $1.18/share. The options have a maximum 10-year term and vest over a 4-year service period, with 25% of the award vesting on the first anniversary of...

Seeking Alpha | February 3, 2022

Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for people with inherited systemic debilitating diseases, today announced that on January 31, 2022, the Company granted three newly hired employees non-statutory options to purchase an aggregate of 66,400 of the Companys ordinary shares.

GlobeNewswire | February 3, 2022

Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and Discovery

Stennicke, an industry veteran, will join Freeline to lead the research and advancement of the Company’s innovative science and platform technologyLONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies for people with inherited systemic debilitating diseases, today announced the expansion of its

Yahoo | February 3, 2022

Read More 'FRLN' Stories Here

FRLN Price Returns

1-mo -15.56%
3-mo -28.30%
6-mo -67.24%
1-year -93.09%
3-year N/A
5-year N/A
YTD -61.62%
2021 -89.16%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5042 seconds.